Building an Integrated Biopharma Company: Crucell (B)

Richard G. Hamermesh; Marianne  Van Der Steen; Susan  Harmeling

Supplement | HBS Case Collection | February 2015 (Revised November 2015)

Building an Integrated Biopharma Company: Crucell (B)

by Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling

Abstract

The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.

Keywords: biotechnology; biopharmacy company; licensing agreements in biopharmacy; licensing; human cell-line technology; vaccine; healthcare innovation; Global health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Pharmaceutical Industry;

Language: English

Format: Print

2 pages

Purchase

Citation:

Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development engine. Blueprint’s drug development strategy was twofold—it focused on creating a single drug compound for multiple disease indications, while at the same time developing drugs to track a disease through its progression. The company’s goal was to become a fully integrated biopharmaceutical company that could move from drug discovery to development to marketing. But it was increasingly challenging to prioritize and manage programs, personnel and partnerships.

Faculty & Research

Building an Integrated Biopharma Company: Crucell (B)

Abstract

Citation:

About the Author

More from the Author

Faculty & Research

Building an Integrated Biopharma Company: Crucell (B)

Abstract

Citation:

Related Work

About the Author

More from the Author